This site is intended for health professionals only
Safety concerns over the use of thiazolidinediones (TZDs) in patients with heart failure (HF) may be unfounded, say researchers, who found no increased risk in patients treated with TZDs versus other antidiabetic agents.
TZDs are contraindicated in patients with moderate to severe HF because of concerns over weight gain and fluid retention. There have also been reports that TZDs might increase the risk of new-onset HF in diabetic patients.
To investigate further, Dr David Aguilar of Baylor College of Medicine in Texas, USA, and colleagues undertook a retrospective cohort study of patients with HF and diabetes mellitus treated in ambulatory clinics at Veterans